White House moves to fire Makary

The FDA is the agency that decides which drugs, vaccines, devices, and many tobacco products can move through the U.S. market. So when the White House moves to push out the FDA commissioner, this is not just palace intrigue. It hits one of the government’s main choke points for health care and a big slice of the economy. (usnews.com) That is the news now — President Donald Trump signed off on a plan to fire FDA Commissioner Marty Makary, though reports on May 8 said the move could still change. (fda.gov) ### Who is Marty Makary? Makary is a Johns Hopkins surgeon and health policy commentator who was confirmed by the Senate on March 25, 2025, as the FDA’s 27th commissioner. (hhs.gov) He came in with a public profile, bestselling books, and credibility inside the MAHA orbit around HHS Secretary Robert F. Kennedy Jr. That made him look, at first, like a durable pick. ### What happened this week? The key change is simple — White House officials signed off on a plan to remove him. Reuters said that approval had already happened. Other reports said Trump was weighing the move or had not made the final call public. Trump himself told reporters on May 9 that he had been reading about it and “know[s] nothing about it,” which suggests either a fluid process or a White House still managing the rollout. (usnews.com) ### Why did Makary end up in trouble? Turns out this was not about one bad day. His tenure had months of friction behind it — criticism over management, controversial drug and vaccine decisions, pressure around abortion-pill policy, and fights over vaping regulation. (fda.gov) Reports also describe broader dissatisfaction from both Trump allies and officials inside the health apparatus. In plain English, Makary seems to have lost support from too many directions at once. ### Why does Vinay Prasad keep coming up? Because personnel tells you where the power struggle is. Vinay Prasad, a close Makary ally and a top FDA official overseeing biologics, is leaving the agency at the end of April or had already stepped down by the time this fight boiled over. (usnews.com) His departure mattered on its own, but it also signaled that Makary’s internal bloc was weakening. When a commissioner loses key lieutenants, the job gets much harder to defend. ### Why does FDA leadership matter so much? The commissioner is not just a spokesperson. The FDA oversees approvals, enforcement, guidance, labeling, inspections, and a huge amount of industry-facing decision making. (politico.com) Drugmakers, device companies, food manufacturers, hospitals, and investors all watch the top job because leadership changes can alter review speed, policy emphasis, and how much risk staff are willing to take. Even if the rules do not change overnight, behavior inside the building often does. ### What changes if he goes? In the short run, uncertainty is the story. Staff may become more cautious. Companies may get slower answers or more process-heavy ones. (pharmtech.com) Politically, an ouster would also show that Trump and the White House are willing to remake health agencies quickly if appointees drift from the line the administration wants. That matters beyond Makary. It tells every other health official how conditional the job really is. ### So what should people watch next? Watch for two things — whether the White House makes the firing official, and who gets the job or the acting role next. (hhs.gov) Also watch whether this turns into a broader FDA reorganization. One report said Makary’s exit could come with wider changes to agency operations, which would make this a structural shake-up, not just a personnel swap. ### Bottom line Basically, this is a power story disguised as a personnel story. Makary was confirmed just over a year ago, but the White House now appears ready to move on. If that happens, the real effect will be felt in the FDA’s day-to-day nerve center — the place where approvals, enforcement, and scientific judgment meet politics. (usnews.com) (fda.gov) (dnyuz.com)